異常なPJA2-CHRM3シグナリングは,胃腫瘍の治療上の脆弱性を生み出します

Lingmeng Li¹, Jingyi Yin¹, Ling Zhang¹

¹Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China.

British journal of cancer

|August 26, 2025

まとめ

新しいPJA2- CHRM3シグナル伝達経路が発見され,拡散型胃がんの潜在的治療標的を明らかにした. この発見は,ホルモン内置と癌の進行におけるその役割についての洞察を提供します.

科学分野:

腫瘍学
胃腸内科
分子生物学

背景:

消化管内置は胃がんの発生と進行において極めて重要です.
胃がん発生におけるアセチルコリン受容体 (AChR) を調節する上流信号伝達経路は十分に理解されていません.

研究の目的:

胃腫瘍形成におけるアセチルコリン受容体 (AChR) の役割を調査する.
拡散型胃がん (DGC) の新たな治療標的を特定する.

主な方法:

薬物のスクリーニングとメカニズムの研究のために生成されたTrp53-/-;Cdh1-/-マウス胃器官および患者由来器官 (PDO)
CHRM3 と PJA2 の間の相互作用を特定するために,質量スペクトロメトリと共免疫プレシピテーションを使用した.
ヒトの胃がんの標本とデータベースを使用して,ユビキチン化,分解,および臨床的相関分析を行った.

主要な成果:

マスカリン・アセチルコリン受容体 (mAChR) 阻害剤は,胃のオーガノイド増殖を効果的に抑制しました.
PJA2はCHRM3をユビキチン化し,TGFβ- pSMAD3の信号伝達と腫瘍の進行を阻害する.
低PJA2発現は,胃がんにおける患者の悪いアウトカムと相関しています.

結論:

拡散型胃がんにおける新しいPJA2-CHRM3信号軸を特定した.
この経路はDGCの新たな治療的脆弱性を示し,がんにおけるコレニル信号への洞察を提供します.

さらに関連する動画

07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

1.6K

10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.2K

関連する概念動画

02:23

Abnormal Proliferation

4.6K

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

4.6K

01:19

Interactions Between Signaling Pathways

6.4K

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

6.4K

01:17

Gastritis-II: Pathophysiology

543

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

543

02:53

Adaptive Mechanisms in Cancer Cells

5.9K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

5.9K

01:07

MAPK Signaling Cascades

6.0K

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

6.0K

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...